| Original language | English (US) |
|---|---|
| Pages (from-to) | e164-e165 |
| Journal | American Journal of Medicine |
| Volume | 133 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2020 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Medicine, Vol. 133, No. 4, 04.2020, p. e164-e165.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - The Reply
AU - Elbadawi, Ayman
AU - Elgendy, Islam Y.
AU - Saad, Marwan
AU - Mahmoud, Karim
AU - Abbott, J. Dawn
AU - Jneid, Hani
AU - Bhatt, Deepak L.
N1 - Funding Information: Funding: None. Conflict of Interest: DLB discloses the following relationships—Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Fractyl, Merck, Novo Nordisk, PLx Pharma, Takeda. The other authors have no conflicts of interest to disclose.
PY - 2020/4
Y1 - 2020/4
UR - https://www.scopus.com/pages/publications/85083446828
UR - https://www.scopus.com/pages/publications/85083446828#tab=citedBy
U2 - 10.1016/j.amjmed.2019.09.009
DO - 10.1016/j.amjmed.2019.09.009
M3 - Letter
C2 - 32331576
AN - SCOPUS:85083446828
SN - 0002-9343
VL - 133
SP - e164-e165
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 4
ER -